Despite promising outcomes using PARP inhibitor therapy in patients with various types of cancer, selecting those patients who will benefit from this therapy remains one of the major challenges, since heterogeneous responses to PARP inhibitor therapy are often observed even in patients preselected for BRCA-mutated cancers, which may be associated with complex intrinsic or acquired resistance [13]. This evidence concerns the gene PARP1 and cancer.